Lotus Pharmaceutical Co Ltd (1795 TW) stock market data APIs
NT$254.0746
0.67(0.3%)
as of March 9, 2026
Try our APIs with
free plan!
Lotus Pharmaceutical Co Ltd Financial Data Overview
Price chart is built with
Anychart
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. In addition, it offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
Prev. Close
254.0746
Open
254.7407
High
259.4571
Low
250.9218
52 wk Range
172.5-369.5
Market Cap
66 491 M
P/E Ratio
14.0244
Shares Outstanding
263 M
Revenue
18 656 M
Dividends (Yield)
0.0216
Beta
0.277
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lotus Pharmaceutical Co Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lotus Pharmaceutical Co Ltd data using free add-ons & libraries
Get Lotus Pharmaceutical Co Ltd Fundamental Data
Lotus Pharmaceutical Co Ltd Fundamental data includes:
- Net Revenue: 18 656 M
- EBITDA: 6 876 M
- Earnings Per Share: 18
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-04
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lotus Pharmaceutical Co Ltd News
New
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
LENZ Therapeutics, Inc. Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSW...
Alvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics Platform
MORRISTOWN, N.J., Sept. 23, 2025 /PRNewswire/ -- Alvogen Pharma US, Inc. ("Alvogen"), a privately owned US-based pharmaceutical company, today announced a definitive agreement by its shareholders to s...
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia
BOSTON & TAIPEI, Taiwan, August 10, 2023--(BUSINESS WIRE)--Corium, LLC ("Corium"), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience ther...
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Amarin Corporation plc Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region DUBLIN, Ireland and BRIDGE...
Get Lotus Pharmaceutical Co Ltd fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
